NYSE:NUVBPharmaceuticals
Nuvation Bio (NUVB) Is Down 22.3% After Shelf Filing And Revenue Jump Has The Bull Case Changed?
Nuvation Bio recently filed a US$125.34 million shelf registration for 21,462,599 shares of Class A common stock tied to an ESOP-related offering and reported fourth-quarter 2025 revenue of US$41.87 million with a reduced net loss of US$36.59 million.
The company’s 2025 results reflected a sharp rise in annual revenue to US$62.90 million and a smaller full-year net loss of US$204.63 million, underpinned by the commercial launch of Ibtrozi and advancing late-stage oncology trials.
With...